Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD.

Hassall D, Brealey N, Wright W, Hughes S, West A, Ravindranath R, Warren F, Daley-Yates P.

Pulm Pharmacol Ther. 2018 Aug;51:59-64. doi: 10.1016/j.pupt.2018.07.001. Epub 2018 Jul 4.

2.

Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans.

Kumar A, Bicer EM, Pfeffer P, Monopoli MP, Dawson KA, Eriksson J, Edwards K, Lynham S, Arno M, Behndig AF, Blomberg A, Somers G, Hassall D, Dailey LA, Forbes B, Mudway I.

Nanomedicine. 2017 Nov;13(8):2517-2521. doi: 10.1016/j.nano.2017.06.008. Epub 2017 Jun 22.

PMID:
28647590
3.

A Biocompatible Synthetic Lung Fluid Based on Human Respiratory Tract Lining Fluid Composition.

Kumar A, Terakosolphan W, Hassoun M, Vandera KK, Novicky A, Harvey R, Royall PG, Bicer EM, Eriksson J, Edwards K, Valkenborg D, Nelissen I, Hassall D, Mudway IS, Forbes B.

Pharm Res. 2017 Dec;34(12):2454-2465. doi: 10.1007/s11095-017-2169-4. Epub 2017 May 30.

4.

Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid.

Kumar A, Bicer EM, Morgan AB, Pfeffer PE, Monopoli M, Dawson KA, Eriksson J, Edwards K, Lynham S, Arno M, Behndig AF, Blomberg A, Somers G, Hassall D, Dailey LA, Forbes B, Mudway IS.

Nanomedicine. 2016 May;12(4):1033-1043. doi: 10.1016/j.nano.2015.12.369. Epub 2016 Jan 6.

PMID:
26767511
5.

Using a single, high mass resolution mass spectrometry platform to investigate ion suppression effects observed during tissue imaging.

Tomlinson L, Fuchser J, Fütterer A, Baumert M, Hassall DG, West A, Marshall PS.

Rapid Commun Mass Spectrom. 2014 May 15;28(9):995-1003. doi: 10.1002/rcm.6869.

PMID:
24677520
6.

Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses.

Forbes B, O'Lone R, Allen PP, Cahn A, Clarke C, Collinge M, Dailey LA, Donnelly LE, Dybowski J, Hassall D, Hildebrand D, Jones R, Kilgour J, Klapwijk J, Maier CC, McGovern T, Nikula K, Parry JD, Reed MD, Robinson I, Tomlinson L, Wolfreys A.

Adv Drug Deliv Rev. 2014 May;71:15-33. doi: 10.1016/j.addr.2014.02.001. Epub 2014 Feb 13.

7.

Quality and content of dental practice websites.

Nichols LC, Hassall D.

Br Dent J. 2011 Apr 9;210(7):E11. doi: 10.1038/sj.bdj.2011.242.

PMID:
21475255
8.

A new, highly selective murine peroxisome proliferator-activated receptor δ agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice.

Ngala RA, Stocker CJ, Roy AG, Hislop D, Wargent E, Bell R, Hassall DG, Harling JD, Billin AN, Willson TM, Arch JR, Cawthorne MA.

Diabetes Obes Metab. 2011 May;13(5):455-64. doi: 10.1111/j.1463-1326.2011.01371.x. Epub 2011 Jan 27.

PMID:
21272187
9.

Challenges in inhaled product development and opportunities for open innovation.

Forbes B, Asgharian B, Dailey LA, Ferguson D, Gerde P, Gumbleton M, Gustavsson L, Hardy C, Hassall D, Jones R, Lock R, Maas J, McGovern T, Pitcairn GR, Somers G, Wolff RK.

Adv Drug Deliv Rev. 2011 Jan-Feb;63(1-2):69-87. doi: 10.1016/j.addr.2010.11.004. Epub 2010 Dec 6. Review.

PMID:
21144875
10.
11.

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F.

Diabetes. 2008 Feb;57(2):332-9. Epub 2007 Nov 16.

12.

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD, Lobe DC, Johnson TG.

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):359-65. Epub 2006 Nov 16.

PMID:
17110604
13.

Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells.

Abbot EL, McCormack JG, Reynet C, Hassall DG, Buchan KW, Yeaman SJ.

FEBS J. 2005 Jun;272(12):3004-14.

14.

Molecular identification of high and low affinity receptors for nicotinic acid.

Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB.

J Biol Chem. 2003 Mar 14;278(11):9869-74. Epub 2003 Jan 9.

15.

Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E.

Harris JD, Schepelmann S, Athanasopoulos T, Graham IR, Stannard AK, Mohri Z, Hill V, Hassall DG, Owen JS, Dickson G.

Gene Ther. 2002 Jan;9(1):21-9.

16.

Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE.

Harris JD, Graham IR, Schepelmann S, Stannard AK, Roberts ML, Hodges BL, Hill V, Amalfitano A, Hassall DG, Owen JS, Dickson G.

Hum Mol Genet. 2002 Jan 1;11(1):43-58.

PMID:
11772998
17.
18.

The sealant restoration: indications, success and clinical technique.

Hassall DC, Mellor AC.

Br Dent J. 2001 Oct 13;191(7):358-62. Review.

19.

Case report: the transmandibular implant system.

Tinsley D, Watson CJ, Russell JL, Hassall DC.

Eur J Prosthodont Restor Dent. 2001 Mar;9(1):31-4.

PMID:
11695132
20.

A chemomechanical method for caries removal.

Morrow LA, Hassall DC, Watts DC, Wilson NH.

Dent Update. 2000 Oct;27(8):398-401.

PMID:
11218535
21.

Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice.

Athanasopoulos T, Owen JS, Hassall D, Dunckley MG, Drew J, Goodman J, Tagalakis AD, Riddell DR, Dickson G.

Hum Mol Genet. 2000 Oct 12;9(17):2545-51.

PMID:
11030760
22.

PPAR agonists as direct modulators of the vessel wall in cardiovascular disease.

Buchan KW, Hassall DG.

Med Res Rev. 2000 Sep;20(5):350-66. Review.

PMID:
10934348
23.

Prevalence and attitudes to fissure sealants in the general dental service in England.

Hassall DC, Mellor AC, Blinkhorn AS.

Int J Paediatr Dent. 1999 Dec;9(4):243-51.

PMID:
10815582
24.

Apolipoprotein E and regulation of cytokine-induced cell adhesion molecule expression in endothelial cells.

Stannard AK, Riddell DR, Bradley NJ, Hassall DG, Graham A, Owen JS.

Atherosclerosis. 1998 Jul;139(1):57-64.

PMID:
9699892
25.

Levels of restorative care under capitation.

Hassall DC, Holloway PJ.

Br Dent J. 1998 Apr 11;184(7):348-50.

PMID:
9599889
26.

Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein.

Graham A, Hassall DG, Rafique S, Owen JS.

Atherosclerosis. 1997 Dec;135(2):193-204.

PMID:
9430369
27.

An assessment of capitation in the General Dental Service contract 2. Patterns of treatment provided to regularly attending patients.

Mellor AC, Blinkhorn AS, Hassall DC, Holloway PJ, Worthington HV.

Br Dent J. 1997 Jun 28;182(12):460-4.

PMID:
9231519
28.

An assessment of capitation in the General Dental Service Contract. 1. The level of caries and its treatment in regularly attending children and adolescents.

Holloway PJ, Blinkhorn AS, Hassall DC, Mellor AC, Worthington HV.

Br Dent J. 1997 Jun 14;182(11):418-23.

PMID:
9217338
29.

An assessment of capitation in the new General Dental Service contract.

Blinkhorn AS, Hassall DC, Holloway PJ, Mellor AC, Worthington HV.

Community Dent Health. 1996 Jun;13 Suppl 1:3-20.

PMID:
8689497
30.

Impaired mobilisation of cholesterol from stored cholesteryl esters in human (THP-1) macrophages.

Graham A, Angell AD, Jepson CA, Yeaman SJ, Hassall DG.

Atherosclerosis. 1996 Feb;120(1-2):135-45.

PMID:
8645354
32.
33.

5-[6-1 -(Cyclohexyl-1 H-tetrazol-5-YL)hexyl]-1,8-naphthyridin-2-(1H)-one, SC-44368, a Potent Anti-aggregatory Agent which Selectively Inhibits Platelet Cyclic AMP Phosphodiesterase.

Booth RF, Manley PW, Buckham SP, Hassall DG, Honey AC, Lad N, Lunt DO, Oswald S, Porter RA, Tuffin DP.

Platelets. 1992;3(3):129-36. doi: 10.3109/09537109209013173.

PMID:
21043905
34.
35.

CD11/CD18 cell surface adhesion glycoproteins: discordance of monocyte function and expression in response to stimulation.

Hassall DG, Bath PM, Gladwin AM, Beesley JE.

Exp Cell Res. 1991 Oct;196(2):346-52.

PMID:
1680065
36.

Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro.

Bath PM, Hassall DG, Gladwin AM, Palmer RM, Martin JF.

Arterioscler Thromb. 1991 Mar-Apr;11(2):254-60.

PMID:
1847823
37.

MAC-1 mediates adherence of human monocytes to endothelium via a protein kinase C dependent mechanism.

Gladwin AM, Hassall DG, Martin JF, Booth RF.

Biochim Biophys Acta. 1990 Apr 9;1052(1):166-72.

PMID:
2182130
38.

Detection of a Protein in Human Platelet Membranes which Binds Low-density Lipoproteins.

Hassall DG, Desai K, Owen JS, Bruckdorfer KR.

Platelets. 1990;1(1):29-35. doi: 10.3109/09537109009009193.

PMID:
21043983
39.

Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation.

Booth RF, Martin JF, Honey AC, Hassall DG, Beesley JE, Moncada S.

Atherosclerosis. 1989 Apr;76(2-3):257-68.

PMID:
2659008
40.

Monocyte-lymphocyte discrimination in a new microtitre-based adhesion assay.

Bath PM, Booth RF, Hassall DG.

J Immunol Methods. 1989 Mar 10;118(1):59-65.

PMID:
2538512
41.

Intracellular mechanisms in the activation of human platelets by low-density lipoproteins.

Andrews HE, Aitken JW, Hassall DG, Skinner VO, Bruckdorfer KR.

Biochem J. 1987 Mar 1;242(2):559-64.

42.

The effect of lanosterol on platelet aggregation in human platelets.

Hassall DG, Bruckdorfer KR, Sulpice JC, Lutton C.

Thromb Haemost. 1985 Dec 17;54(4):760-3.

PMID:
4089810
43.
44.

The increased sensitivity of platelets to prostacyclin in marathon runners.

Dix CJ, Hassall DG, Bruckdorfer KR.

Thromb Haemost. 1984 Jul 29;51(3):385-7.

PMID:
6093280
45.

The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin.

Hassall DG, Owen JS, Bruckdorfer KR.

Biochem J. 1983 Oct 15;216(1):43-9.

46.

Influence of plasma lipoproteins on platelet aggregation in a normal male population.

Hassall DG, Forrest LA, Bruckdorfer KR, Marenah CB, Turner P, Cortese C, Miller NE, Lewis B.

Arteriosclerosis. 1983 Jul-Aug;3(4):332-8.

PMID:
6882287
47.

Hypocholesterolaemia and non-cardiovascular disease: metabolic studies on subjects with low plasma cholesterol concentrations.

Marenah CB, Lewis B, Hassall D, La Ville A, Cortese C, Mitchell WD, Bruckdorfer KR, Slavin B, Miller NE, Turner PR, Heduan E.

Br Med J (Clin Res Ed). 1983 May 21;286(6378):1603-6.

48.

A home visit program for students.

Hassall D.

Nurs Outlook. 1974 Aug;22(8):522-4. No abstract available.

PMID:
4495263

Supplemental Content

Loading ...
Support Center